BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9815659)

  • 21. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma.
    Salgami EV; Efstathiou SP; Vlachakis V; Sekara EV; Syrigos KN; Roussou PP
    Haematologia (Budap); 2002; 32(4):377-87. PubMed ID: 12803112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma.
    Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Rassidakis GZ; Doussis-Anagnostopoulou IA; Hatzioannou M; Vaiopoulos G; Kittas C; Sarris AH; Pizzolo G; Pangalis GA
    Haematologica; 2001 Mar; 86(3):274-81. PubMed ID: 11255274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
    Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
    Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
    Negrier S; Perol D; Menetrier-Caux C; Escudier B; Pallardy M; Ravaud A; Douillard JY; Chevreau C; Lasset C; Blay JY;
    J Clin Oncol; 2004 Jun; 22(12):2371-8. PubMed ID: 15197198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma.
    Nacinović-Duletić A; Stifter S; Dvornik S; Skunca Z; Jonjić N
    Int J Lab Hematol; 2008 Jun; 30(3):230-9. PubMed ID: 18479302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The lymphomas.
    DeVita VT; Canellos GP
    Semin Hematol; 1999 Oct; 36(4 Suppl 7):84-94. PubMed ID: 10595757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
    Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
    Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
    Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
    Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
    Robertson MJ; Pelloso D; Abonour R; Hromas RA; Nelson RP; Wood L; Cornetta K
    Clin Cancer Res; 2002 Nov; 8(11):3383-93. PubMed ID: 12429625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
    Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
    Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
    Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
    Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.
    Lambeck AJ; Crijns AP; Leffers N; Sluiter WJ; ten Hoor KA; Braid M; van der Zee AG; Daemen T; Nijman HW; Kast WM
    Clin Cancer Res; 2007 Apr; 13(8):2385-91. PubMed ID: 17438097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
    Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
    Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
    Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
    Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Update on lymphomas].
    Eghbali H; Soubeyran P; Soubeyran I; Monnerau A; Cazorla S
    Bull Cancer; 2002 Jan; 89(1):89-99. PubMed ID: 11847030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
    Beard SM; Lorigan PC; Sampson FC
    Br J Cancer; 2000 Jan; 82(1):81-4. PubMed ID: 10638970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-time polymerase chain reaction determination of cytokine mRNA expression profiles in Hodgkin's lymphoma.
    Malec M; Söderqvist M; Sirsjö A; MacNamara B; Lewin N; Sjöberg J; Björkholm M; Porwit-MacDonald A
    Haematologica; 2004 Jun; 89(6):679-85. PubMed ID: 15194535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.